Full Text View
Tabular View
No Study Results Posted
Related Studies
Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas
This study has been completed.
First Received: June 2, 2000   Last Updated: July 23, 2008   History of Changes
Sponsored by: SuperGen
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00005874
  Purpose

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have locally advanced or metastatic soft tissue sarcomas.


Condition Intervention Phase
Gastrointestinal Stromal Tumor
Sarcoma
Small Intestine Cancer
Drug: rubitecan
Phase II

MedlinePlus related topics: Cancer Intestinal Cancer Soft Tissue Sarcoma
Drug Information available for: Rubitecan
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment
Official Title: Phase II Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) in Patients With Soft-Tissue Sarcomas

Further study details as provided by National Cancer Institute (NCI):

Study Start Date: June 1999
Detailed Description:

OBJECTIVES: I. Assess the efficacy and toxicity of nitrocamptothecin in patients with locally advanced or metastatic gastrointestinal leiomyosarcomas or other soft tissue sarcomas.

OUTLINE: Patients are stratified by disease (gastrointestinal leiomyosarcomas vs other soft tissue sarcomas). Patients receive oral nitrocamptothecin daily on days 1-5. Treatment continues weekly in the absence of disease progression or unacceptable toxicity. Responding patients who undergo surgery then receive an additional 4-6 courses (4 weeks/course).

PROJECTED ACCRUAL: A total of 34-78 patients (17-39 per stratum) will be accrued for this study.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS: Histologically confirmed locally advanced or metastatic inoperable soft tissue sarcoma Measurable or evaluable disease that has not been irradiated Must have received, refused, or be not eligible for doxorubicin/ifosfamide treatment Previously untreated gastrointestinal leiomyosarcoma allowed

PATIENT CHARACTERISTICS: Age: Not specified Performance status: Zubrod 0-2 Life expectancy: At least 12 weeks Hematopoietic: Absolute granulocyte count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL Transaminases no greater than 3 times normal Renal: Creatinine less than 2.0 mg/dL Cardiovascular: No New York Heart Association class III or IV heart disease No active coronary disease requiring therapy Pulmonary: No severe pulmonary insufficiency Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 3 months after study No other prior malignancy in past 3 years except nonmelanoma skin cancer or carcinoma in situ of the cervix No concurrent active infections No psychosis or mental disability that would preclude study

PRIOR CONCURRENT THERAPY: Biologic therapy: At least 7 days since prior biological therapy and recovered No concurrent immunotherapy Chemotherapy: See Disease Characteristics At least 3 weeks since prior chemotherapy and recovered No other concurrent chemotherapy Endocrine therapy: At least 7 days since prior hormonal therapy and recovered Radiotherapy: See Disease Characteristics Surgery: Not specified

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00005874

Locations
United States, California
SuperGen, Incorporated
Dublin, California, United States, 94568
Sponsors and Collaborators
SuperGen
Investigators
Study Chair: Show-Li Sun, MD SuperGen
  More Information

Additional Information:
No publications provided

Study ID Numbers: CDR0000067910, SUPERGEN-RFS2000-24, MDA-DM-99109
Study First Received: June 2, 2000
Last Updated: July 23, 2008
ClinicalTrials.gov Identifier: NCT00005874     History of Changes
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
adult leiomyosarcoma
stage III adult soft tissue sarcoma
recurrent adult soft tissue sarcoma
small intestine leiomyosarcoma
metastatic childhood soft tissue sarcoma
recurrent childhood soft tissue sarcoma
childhood leiomyosarcoma
gastrointestinal stromal tumor
stage IV adult soft tissue sarcoma

Study placed in the following topic categories:
Jejunal Neoplasms
Digestive System Neoplasms
Leiomyosarcoma
Gastrointestinal Diseases
9-nitrocamptothecin
Intestinal Diseases
Ileal Diseases
Camptothecin
Recurrence
Intestinal Neoplasms
Duodenal Neoplasms
Neoplasms, Connective and Soft Tissue
Soft Tissue Sarcomas
Malignant Mesenchymal Tumor
Digestive System Diseases
Ileal Neoplasms
Sarcoma
Gastrointestinal Neoplasms
Gastrointestinal Stromal Tumors
Duodenal Diseases

Additional relevant MeSH terms:
Jejunal Neoplasms
Neoplasms by Histologic Type
Digestive System Neoplasms
Gastrointestinal Diseases
Intestinal Diseases
Ileal Diseases
Intestinal Neoplasms
Duodenal Neoplasms
Neoplasms, Connective and Soft Tissue
Neoplasms
Neoplasms by Site
Digestive System Diseases
Ileal Neoplasms
Jejunal Diseases
Sarcoma
Gastrointestinal Neoplasms
Gastrointestinal Stromal Tumors
Duodenal Diseases

ClinicalTrials.gov processed this record on May 07, 2009